Cyclacel Pharmaceuticals, Inc. (CYCC) has secured $3.0 million in gross proceeds through a private placement of its convertible Series F Preferred Stock to accredited investors.
Each investor received a Series A common stock purchase warrant to buy 3,270,000 shares at an exercise price of $0.51 per share.
The offering was completed on June 20, 2025.
Net proceeds from this financing by Cyclacel Pharmaceuticals, Inc. (CYCC) will support working capital and general corporate purposes.
